NCT01745510View on ClinicalTrials.gov

Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Necrotizing Enterocolitis
Interventions
DIETARY_SUPPLEMENT

Docosahexaenoic acid (DHA)

Docosahexaenoic acid from algae source

DIETARY_SUPPLEMENT

Placebo

Placebo was designed to mimic the color and consistence of the oil that contains DHA

Trial Locations (1)

06720

Unit of Medical Research in Nutrition, Pediatric Hospital, IMSS, Mexico City

All Listed Sponsors
collaborator

National Council of Science and Technology, Mexico

OTHER

lead

Coordinación de Investigación en Salud, Mexico

OTHER_GOV

NCT01745510 - Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates | Biotech Hunter | Biotech Hunter